Kezar Life Sciences, Inc.
NASDAQ Global SelectTotal Valuation
Kezar Life Sciences, Inc. carries a market capitalization of 53.86M, placing it among publicly traded companies globally. Its enterprise value stands at -23.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 53.86M |
| Enterprise Value | -23.55M |
Share Statistics
Kezar Life Sciences, Inc. currently has 7.33M shares outstanding.
| Shares Outstanding | 7.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | -0.89 |
| P/OCF Ratio | -0.89 |
Financial Position
Kezar Life Sciences, Inc. maintains a current ratio of 11.52, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.32, indicating elevated leverage, while an interest coverage ratio of -37.50 demonstrates limited ability to service its debt obligations.
| Current Ratio | 11.52 |
| Quick Ratio | 11.24 |
| Debt / Equity | 3.32 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -37.50 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Kezar Life Sciences, Inc.'s stock has gained approximately 55.76923% over the past 52 weeks. The 50-day moving average sits at 7.13, while the 200-day moving average is 5.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 55.76923% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 5.81 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -51.37M, while operating income came in at -52.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -52.27M |
| Pretax Income | -56.03M |
| Net Income | -56.03M |
| EBITDA | -51.37M |
| EBIT | -52.27M |
| Earnings Per Share (EPS) | -7.66 |
Balance Sheet
Kezar Life Sciences, Inc. holds 71.88M in cash and equivalents against 2.33M in total debt, resulting in a net debt position of -71.88M. Total book value stands at -490.52M, with working capital of 69.16M providing operational flexibility.
| Cash & Cash Equivalents | 71.88M |
| Total Debt | 2.33M |
| Net Debt | -71.88M |
| Equity (Book Value) | -490.52M |
| Book Value Per Share | -67.07 |
| Working Capital | 69.16M |
Cash Flow
Kezar Life Sciences, Inc. produced -51.78M in operating cash flow over the past twelve months. After subtracting -8,000.00 in capital expenditures, free cash flow totaled -51.78M - equivalent to -7.08 per share.
| Operating Cash Flow | -51.78M |
| Capital Expenditures | -8,000.00 |
| Free Cash Flow | -51.78M |
| FCF Per Share | -7.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 23.01 |
| FCF Yield | -112.54 |
Stock Splits
Kezar Life Sciences, Inc.'s most recent stock split took place on October 30, 2024 with a 10:1 split ratio.
| Last Split Date | 10/30/2024 |
| Split Ratio | 10:1 |
Scores
Kezar Life Sciences, Inc. posts an Altman Z-Score of -5.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.93 |